Key Highlights
- Cencora to acquire RCA for $4.6 billion, expanding its MSO solutions.
- RCA to retain minority ownership; Cencora holds 85%.
- Transaction to be accretive by $0.35 to adjusted diluted EPS in the first 12 months post-closing.
- RCA brings nearly 300 specialists across 23 states and a clinical network with 40 trial sites.
- New partnership to enhance retinal care innovations and broaden value across stakeholders.
Source: Business Wire
Notable Quotes
- “The acquisition of RCA will allow Cencora to broaden our relationships with community providers in a high growth segment and build on our leadership in specialty.” — Bob Mauch, President & CEO at Cencora
- “With additional resources to support the continued execution of our growth strategy, we will be better positioned to continue expanding our physician network and enhancing the quality of care we provide.” — Robby Grabow, CEO at RCA
- “Our cultural alignment and shared focus on driving innovation will allow us to unlock new opportunities together and advance the caliber of retina care.” — David Brown, MD, Co-Chair of Retina Consultants of America’s Medical Leadership Board at Retina Consultants of America (RCA)
SoHC's Take
This acquisition of RCA by Cencora exemplifies the continued consolidation and expansion in the specialty care sector, particularly within management services organizations (MSOs). Cencora’s investment highlights the strategic emphasis on expanding its specialty services to meet the demand for integrated provider support, especially in high-growth areas like retinal care. With RCA’s extensive clinical research capabilities and physician network, this deal positions Cencora to enhance service offerings for both physicians and pharmaceutical partners. The transaction’s financial structuring, with a minority interest retained by RCA and contingent considerations, also reflects Cencora’s approach to balanced growth and collaborative integration, likely strengthening its standing within the broader healthcare ecosystem.
